

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 September 2020 (17.09.2020)



(10) International Publication Number
WO 2020/186238 A1

(51) International Patent Classification:

A61K 35/763 (2015.01) C12N 7/01 (2006.01)
A61P 35/04 (2006.01) C12N 15/00 (2006.01)

(21) International Application Number:

PCT/US2020/022806

(22) International Filing Date:

13 March 2020 (13.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/818,577 14 March 2019 (14.03.2019) US
62/932,725 08 November 2019 (08.11.2019) US

(71) Applicant: **RESEARCH INSTITUTE AT NATION-
WIDE CHILDREN'S HOSPITAL** [US/US]; 700
Children's Drive, Columbus, Ohio 43205 (US).

(72) Inventors: **CRIFE, Timothy, P.**; c/o Research Institute
at Nationwide Children's Hospital, 700 Children's Drive,
Columbus, Ohio 43205 (US). **CASSADY, Kevin, A.**; c/o
Research Institute at Nationwide Children's Hospital, 700
Children's Drive, Columbus, Ohio 43205 (US). **WANG,
Pin-Yi**; c/o Research Institute at Nationwide Children's
Hospital, 700 Children's Drive, Columbus, Ohio 43205
(US). **LOVE, Julia, K.**; c/o Research Institute at Nation-
wide Children's Hospital, 700 Children's Drive, Columbus,
Ohio 43205 (US).

(74) Agent: **KONSKI, Antoinette, F.** et al.; Foley & Lardner
LLP, 3000 K Street, N. W., Suite 600, Washington, District
of Columbia 20007-5109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SYNCYTIAL ONCOLYTIC HERPES SIMPLEX MUTANTS AS POTENT CANCER THERAPEUTICS




FIG. 1B

(57) Abstract: The disclosure provides a non-natural herpes simplex virus ("HSV"), compositions comprising, or alternatively consisting essentially of, or yet further consisting of the HSV, and methods of producing the HSV, or infecting a cell with the HSV. Also provided herein are methods of treating cancer or inhibiting the growth or metastasis of cancer cell in a subject in need thereof.

WO 2020/186238 A1